217 results
8-K
KA
Kineta Inc
17 Feb 22
Yumanity Therapeutics Exploring Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring
8:37am
, strategy, plans, prospects or intentions. Such statements include, without limitation, statements regarding the Company’s business strategy, structure … in and effect of implementing the Company’s business strategy; the difficulties in and effect of implementing the Company’s reduction in workforce
8-K
EX-99.1
KA
Kineta Inc
17 Oct 18
Proteostasis Therapeutics Announces Positive Preliminary Results from
4:30pm
Strategy in CF
In addition to completed studies ofPTI-801 andPTI-428 in patients on background Orkambi® therapy, and the ongoing study of the PTI doublet … ’ clinical strategy is expected to inform a Phase 3 development path using PTI’s proprietary product candidates either together and/or asadd-ons to current
8-K
EX-99.1
KA
Kineta Inc
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
of 2023) and its ability to successfully initiate and complete clinical trials; (v) the nature, strategy and focus of the combined company; (vi … and manufacturing capabilities and strategy; (xiv) Kineta’s ability to identify additional product candidates with significant commercial potential
8-K
EX-99.1
KA
Kineta Inc
30 Dec 20
Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics
4:44pm
of the combined company’s capital to support its future operations and its ability to successfully initiate and complete clinical trials; (v) the nature, strategy … candidates; (xiii) Yumanity’s commercialization, marketing and manufacturing capabilities and strategy; (xiv) Yumanity’s ability to identify additional
8-K
EX-99.2
KA
Kineta Inc
17 Oct 18
Proteostasis Therapeutics Announces Positive Preliminary Results from
4:30pm
PTI Is Pursuing A Dual Track Development Strategy Add-on and Proprietary Combinations One Molecule Two Molecules Three Molecules Four Molecules Five … – olacaftor, Vertex or VRTX – Vertex Pharmaceuticals Inc.
Two Prong Strategy Add-on and Proprietary Combination POC Expected in 1Q’19 Add-on PTI-428 + luma
8-K
5h319dmz5vuj
17 Oct 18
Proteostasis Therapeutics Announces Positive Preliminary Results from
4:30pm
8-K
EX-99.1
ik7iksy
28 Nov 18
Regulation FD Disclosure
8:00am
8-K
EX-99.1
gke5ropj9fwm i8
7 Jan 19
Departure of Directors or Certain Officers
7:31am
8-K
EX-99.2
vm3shyjdhociofle
10 Nov 21
Regulation FD Disclosure
7:12am
8-K
EX-99.1
h85hlskfdbfg1jdg696h
11 Aug 23
Regulation FD Disclosure
4:08pm
8-K
EX-99.1
ku28o5
31 Mar 23
Regulation FD Disclosure
12:00am
8-K
EX-99.1
87b7b40r
9 Jun 23
Submission of Matters to a Vote of Security Holders
9:00am
425
0s6psh0u5t0 eht8r2
29 Aug 22
Business combination disclosure
4:03pm
8-K
EX-99.1
40n3d
23 May 23
Kineta to Present at Jefferies Healthcare Conference
9:30am
8-K
EX-99.1
4xuz1rcwmnpa3ks axtw
3 Apr 23
Kineta to Present at 22nd Annual Needham Healthcare Conference
7:01am
8-K
ib1n6
6 Feb 19
Departure of Directors or Certain Officers
8:00am
425
97z25yzo2nbb
14 Nov 22
Business combination disclosure
8:50am
8-K
EX-99.1
xb73y3ip6crvlt 4cwi
31 Aug 23
Kineta to Participate in Upcoming Investor Conferences
9:30am
8-K
EX-99.1
t54of5h
29 Jun 23
Kineta to Receive $5 Million Milestone Payment from Merck
7:01am
8-K
EX-99.2
z0eesm
17 Oct 23
Entry into a Material Definitive Agreement
8:32am